{"id":"W2622613223","doi":"10.1200/jco.2017.35.15_suppl.1088","title":"Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Nausea; Cohort; Clinical endpoint; Cancer; Surgery; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00204077,0.001059376,0.0009918063,0.0003164086,0.0003963766,0.000825037,0.0008308491,0.0009557515,0.006052669],"category_scores_gemma":[0.001385444,0.0004897028,0.0008945906,0.0002810548,0.000400567,0.000779104,0.0004374155,0.00238454,0.001476328],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009799023,"about_ca_system_score_gemma":0.001855662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001276747,"about_ca_topic_score_gemma":0.003406032,"domain_scores_codex":[0.9996895,0.0001396832,0.00001769367,0.00005646688,0.00003904154,0.00005774589],"domain_scores_gemma":[0.99915,0.0001076168,0.0001730987,0.00008943074,0.0000861726,0.0003937783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.729683,0.07518337,0.01628682,0.001305504,0.002283963,0.0004334883,0.0003513854,0.002277657,0.06111784,0.0004057253,0.01997043,0.09070081],"study_design_scores_gemma":[0.6517377,0.2988514,0.02909768,0.0001074294,0.001083612,0.0009102153,0.0001007019,0.001660759,0.005765222,0.0004424666,0.01020417,0.00003869073],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725762,0.002680714,0.001376597,0.0008967595,0.0001725395,0.007091611,0.01057837,0.0001943829,0.004432855],"genre_scores_gemma":[0.9608357,0.002403319,0.004526538,0.001965074,0.0001761158,0.00619615,0.01769121,0.00008200321,0.006123764],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006052669,"threshold_uncertainty_score":0.02024823,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2259555002164314,"score_gpt":0.540515536048429,"score_spread":0.3145600358319975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}